Data / Drug companies / Alembic Pharmaceuticals Inc.
Alembic Pharmaceuticals Inc.: 499 products in the FDA NDC directory, labeler code 62332
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Alembic Pharmaceuticals Inc. (labeler code 62332) lists 499 products in the FDA National Drug Code Directory, covering 175 finished drugs by generic name. By type: 495 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
The request: Watch Alembic Pharmaceuticals Inc. (FDA labeler code 62332): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62332
- Products in commercial distribution
- 499
- Packages
- 1,334
- Finished drugs by generic name
- 175
- Prescription products
- 495
- Over the counter products
- 4
- Controlled substance products
- Schedule III 2, Schedule IV 15, Schedule V 12
- Flagged as original packager
- 459 of 459 products that carry the flag
- Started marketing in the last 12 months
- 51
- Earliest marketing start
- February 18, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 498 | 99.8% |
| New drug applications (NDA) | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 495 | 99.2% |
| Over the counter drugs | 4 | 0.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 145 | 29.1% |
| Tablet | 88 | 17.6% |
| Capsule | 70 | 14% |
| Tablet, extended release | 30 | 6% |
| Solution/ drops | 23 | 4.6% |
| Injection | 16 | 3.2% |
| Tablet, orally disintegrating | 14 | 2.8% |
| Tablet, coated | 13 | 2.6% |
| Capsule, extended release | 13 | 2.6% |
| Injection, solution | 11 | 2.2% |
| Tablet, film coated, extended release | 11 | 2.2% |
| Cream | 10 | 2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ciprofloxacin otic | 62332-168 | Solution/ drops | Generic drugs (ANDA) | November 2, 2026 |
| Valganciclovir | 62332-754 | Powder, for solution | Generic drugs (ANDA) | October 28, 2026 |
| Ciprofloxacin and Dexamethasone | 62332-776 | Suspension/ drops | Generic drugs (ANDA) | October 15, 2026 |
| Clonidine hydrochloride | 62332-169 | Tablet | Generic drugs (ANDA) | September 22, 2026 |
| Prucalopride | 62332-078 | Tablet, film coated | Generic drugs (ANDA) | July 31, 2026 |
| Prucalopride | 62332-077 | Tablet, film coated | Generic drugs (ANDA) | July 31, 2026 |
| Dapsone | 62332-551 | Gel | Generic drugs (ANDA) | July 1, 2026 |
| Oseltamivir phosphate | 62332-769 | For suspension | Generic drugs (ANDA) | June 29, 2026 |
| Tretinoin | 62332-808 | Cream | Generic drugs (ANDA) | June 11, 2026 |
| Macitentan | 62332-373 | Tablet, film coated | Generic drugs (ANDA) | June 6, 2026 |
| Bosutinib | 62332-312 | Tablet, film coated | Generic drugs (ANDA) | May 19, 2026 |
| Bosutinib | 62332-311 | Tablet, film coated | Generic drugs (ANDA) | May 19, 2026 |
| Fingolimod | 62332-228 | Capsule | Generic drugs (ANDA) | April 28, 2026 |
| Methotrexate | 62332-712 | Injection, solution | Generic drugs (ANDA) | April 15, 2026 |
| Methotrexate | 62332-711 | Injection, solution | Generic drugs (ANDA) | April 15, 2026 |
| Duloxetine hydrochloride | 62332-280 | Capsule, delayed release | Generic drugs (ANDA) | April 9, 2026 |
| Duloxetine hydrochloride | 62332-279 | Capsule, delayed release | Generic drugs (ANDA) | April 9, 2026 |
| Duloxetine hydrochloride | 62332-278 | Capsule, delayed release | Generic drugs (ANDA) | April 9, 2026 |
| Dapagliflozin | 62332-393 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin | 62332-392 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Paroxetine | 62332-766 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 31, 2026 |
| Telmisartan and Amlodipine | 62332-187 | Tablet | Generic drugs (ANDA) | March 31, 2026 |
| Telmisartan and Amlodipine | 62332-186 | Tablet | Generic drugs (ANDA) | March 31, 2026 |
| Telmisartan and Amlodipine | 62332-185 | Tablet | Generic drugs (ANDA) | March 31, 2026 |
| Telmisartan and Amlodipine | 62332-184 | Tablet | Generic drugs (ANDA) | March 31, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.